Literature DB >> 24823387

Modulation of Fas-Fas Ligand Interaction Rehabilitates Hypoxia-Induced Apoptosis of Mesenchymal Stem Cells in Ischemic Myocardium Niche.

Onju Ham1, Se-Yeon Lee, Byeong-Wook Song, Min-Ji Cha, Chang Youn Lee, Jun-Hee Park, Il-Kwon Kim, Jiyun Lee, Hyang-Hee Seo, Min-Ji Seung, Eunhyun Choi, Yangsoo Jang, Ki-Chul Hwang.   

Abstract

Mesenchymal stem cells (MSCs) have the potential to repair and regenerate ischemic heart tissue; however, the poor viability of transplanted MSCs in the ischemic region is a major obstacle to their therapeutic use. This cell death is caused by Fas and Fas ligand (FasL) interactions under harsh conditions. To investigate improving the survival and therapeutic effects of MSCs, we focused our research on Fas-FasL-mediated cell death. In this study, we found that the poor viability of transplanted MSCs was caused by Fas-FasL interactions between host ischemic myocardial cells and implanted MSCs. In addition, we found that increased Fas expression and the corresponding decrease of cell survival were in close relation to hypoxic MSCs treated with FasL and H2O2. When MSCs were treated with a recombinant Fas/Fc chimera (Fas/Fc) inhibiting Fas-FasL interactions, the expressions of proapoptotic proteins including caspase-8, caspase-3, Bax, and cytochrome-c were attenuated, and the survival of MSCs was recovered. In ischemia-reperfusion injury models, the interaction between FasL in ischemic heart and Fas in implanted MSCs caused a loss of transplanted MSCs, whereas the inhibition of this interaction by Fas/Fc treatment improved cell survival and restored heart function. Thus, our study suggests that Fas-FasL interactions are responsible for activating cell death signaling in implanted stem cells and could be a potential target for improving therapeutic efficacy of stem cells in treating ischemic heart diseases.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24823387     DOI: 10.3727/096368914X681748

Source DB:  PubMed          Journal:  Cell Transplant        ISSN: 0963-6897            Impact factor:   4.064


  4 in total

1.  Bcl-xL Genetic Modification Enhanced the Therapeutic Efficacy of Mesenchymal Stem Cell Transplantation in the Treatment of Heart Infarction.

Authors:  Xiaodong Xue; Yu Liu; Jian Zhang; Tao Liu; Zhonglu Yang; Huishan Wang
Journal:  Stem Cells Int       Date:  2015-05-05       Impact factor: 5.443

2.  Resistance of Human Liver Mesenchymal Stem Cells to FAS-Induced Cell Death.

Authors:  Irina V Kholodenko; Alisa M Gisina; Garik V Manukyan; Alexander G Majouga; Elena V Svirshchevskaya; Roman V Kholodenko; Konstantin N Yarygin
Journal:  Curr Issues Mol Biol       Date:  2022-07-30       Impact factor: 2.976

3.  FAIM Enhances the Efficacy of Mesenchymal Stem Cell Transplantation by Inhibiting JNK-Induced c-FLIP Ubiquitination and Degradation.

Authors:  Jinyong Chen; Feng Liu; Wangxing Hu; Yi Qian; Dilin Xu; Chenyang Gao; Zhiru Zeng; Si Cheng; Lan Xie; Kaixiang Yu; Gangjie Zhu; Xianbao Liu
Journal:  Stem Cells Int       Date:  2022-09-30       Impact factor: 5.131

4.  Fas-L promotes the stem cell potency of adipose-derived mesenchymal cells.

Authors:  Inna Solodeev; Benjamin Meilik; Ilan Volovitz; Meirav Sela; Sharon Manheim; Shai Yarkoni; Dov Zipori; Eyal Gur; Nir Shani
Journal:  Cell Death Dis       Date:  2018-06-11       Impact factor: 8.469

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.